Last reviewed · How we verify
CONVENTIONAL ABVD
This chemotherapy regimen combines Adriamycin, Bleomycin, Vinblastine, and Dacarbazine to target rapidly dividing cancer cells.
This chemotherapy regimen combines Adriamycin, Bleomycin, Vinblastine, and Dacarbazine to target rapidly dividing cancer cells. Used for Hodgkin lymphoma, Non-Hodgkin lymphoma.
At a glance
| Generic name | CONVENTIONAL ABVD |
|---|---|
| Also known as | BLEOMICINE TEVA, DOXORUBICINE TEVA, VELBE, NATULAN |
| Sponsor | Ospedale Santa Croce-Carle Cuneo |
| Drug class | chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
The combination of these drugs works synergistically to induce apoptosis in cancer cells, with Adriamycin and Dacarbazine causing DNA damage, Bleomycin inducing DNA strand breaks, and Vinblastine inhibiting microtubule formation.
Approved indications
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Nausea and vomiting
- Fatigue
Key clinical trials
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (PHASE3)
- A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma (PHASE3)
- Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) (PHASE2)
- A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) (PHASE1, PHASE2)
- Anti-CD30 (Brentuximab Vedotin) With AVD Versus ABVD Chemotherapy Protocol Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma (NA)
- FIL Study on ABVD DD-DI as Upfront Therapy in HL. (PHASE3)
- The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD (PHASE2)
- Circulating Tumor DNA Genotyping for Biological Monitoring of Patients Treated in the FIL-Rouge Clinical Trial
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CONVENTIONAL ABVD CI brief — competitive landscape report
- CONVENTIONAL ABVD updates RSS · CI watch RSS
- Ospedale Santa Croce-Carle Cuneo portfolio CI